Home › Trial NCT07790939
89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian Cancer
- Trial IDNCT07790939
- StatusNot Yet Recruiting
- PhaseEarly Phase 1
- Study typeInterventional
- SponsorPeking University Cancer Hospital & Institute
- Enrollment20
- Start date2026-09-01
- ConditionsEpithelial Ovarian Cancer · Ovarian Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.